Trial Profile
First-Line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL) With Mutated IGHV Gene and Non-Del(17p)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Obinutuzumab (Primary) ; Allopurinol; Cyclophosphamide; Fludarabine; Valaciclovir
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 12 Dec 2023 Results (N=45) of updated analysis with a median follow-up of 72 months presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 03 Nov 2023 Planned End Date changed from 31 Mar 2024 to 31 Mar 2025.
- 03 Nov 2023 Planned primary completion date changed from 31 Mar 2024 to 31 Mar 2025.